Trevena Losses Alert: Bernstein Liebhard LLP Announces Investigation Of Trevena, Inc. - TRVN

NEW YORK, Oct. 10, 2018

If you purchased Trevena securities, and/or would like to discuss your legal rights and options, please visit Trevena Shareholder Investigation or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.

On May 2, 2016, Trevena announced that it had "reached general agreement" with the FDA on key elements of its Phase 3 program for oliceridine (TRV130) and was "very pleased" with the outcome of its discussions with the FDA.

However, on October 9, 2018, minutes from the FDA's April 28, 2016 meeting with Trevena were released and showed that the FDA:

• "did not agree with the proposed dosing in the Phase 3 studies";
• "did not agree with the proposed primary endpoint"; and
• "did not agree with the proposed non-inferiority (NI) margin for comparing morphine to oliceridine."

If you purchased Trevena securities, and/or would like to discuss your legal rights and options, please visit https://www.bernlieb.com/cases/trevena-inc-trvn-lawsuit-class-action-fraud-stock-88/ or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.